Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002).

Xin HuaXi-Wen BiJian-Li ZhaoYan-Xia ShiYing LinZhi-Yong WuYuan-Qi ZhangLe-Hong ZhangAn-Qing ZhangHeng HuangXin-Mei LiuFei XuYing GuoWen XiaRuo-Xi HongKui-Kui JiangCong XueXin AnYong-Yi ZhongShu-Sen WangJia-Jia HuangZhong-Yu Yuan

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Trastuzumab plus endocrine therapy was non-inferior to trastuzumab plus chemotherapy in patients with HR+HER2+ MBC.

Keyphrases

metastatic breast cancer
epidermal growth factor receptor
locally advanced
stem cells
squamous cell carcinoma
radiation therapy
bone marrow
rectal cancer
smoking cessation